News

With an average analyst rating of hold, Novartis is clearly not a favorite. But some of the best stock picks are contrarian ...
Two of the world's largest pharmaceutical companies are suing Oklahoma to stop a new state law dealing with a $70 billion ...
LONDON, GREATER LONDON, UNITED KINGDOM, July 4, 2025 /EINPresswire.com/ -- The anti-inflammatory drugs market size has grown rapidly in recent years. From $136.86 billion in 2024, it is predicted to ...
"Novartis’ Cosentyx shows no benefit in Phase III GCA trial" was originally created and published by Clinical Trials Arena, a ...
Sustainable Pulse. Source: Le Monde, by Stéphane Foucart (article translated from French to English by Sustainable Pulse) ...
Novartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet ...
A memo that purports to summarize a meeting held by members of a biotech trade group suggests deep concern about RFK Jr.’s ...
Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.
Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...
Novartis (NVS) stock slips as the company's anti-inflammatory agent Cosentyx fails primary goal in a Phase 3 trial for giant ...
In the past week, bluebird bio named new leaders after its acquisition, Dyne secured a debt deal and ProFound Therapeutics ...